Suplatast Tosylate is an inhibitor of Th2 cytokine synthesis which can attenuate IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production.
Type 2 helper T cells (Th2) are essential for allergen-induced bronchial hyperresponsiveness and eosinophilic inflammation. Suplatast tosilate is an anti-allergic drug that suppresses IgE synthesis in both mice and humans without affecting total IgG and IgM production[3]. Suplatast tosilate at 1–10µg/mL suppresses human IgE synthesis in a concentration-dependent manner. Suplatast tosilate at 10µg/mL reduced the mRNA level of IL-4 in phytohemagglutinin-stimulated human peripheral blood mononuclear cells[4]. In ovalbumin (OVA)-challenged mice, treatment with 100mg/kg suplatast tosilate significantly decreases the number of total cells and eosinophils in bronchoalveolar lavage fluid compared with OVA control mice. Mice treated with suplatast tosilate also show significantly lower levels of IL-4, IL-5, and IL-13 in mice in comparison with the controls[3].
搜索
